6.
Clark S, Rodriguez A, Snyder R, Hankins G, Boehning D
. Structure-Function Of The Tumor Suppressor BRCA1. Comput Struct Biotechnol J. 2012; 1(1).
PMC: 3380633.
DOI: 10.5936/csbj.201204005.
View
7.
Gallardo-Rincon D, Alvarez-Gomez R, Montes-Servin E, Toledo-Leyva A, Montes-Servin E, Michel-Tello D
. Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients. Transl Oncol. 2019; 13(2):212-220.
PMC: 6931216.
DOI: 10.1016/j.tranon.2019.11.003.
View
8.
Rebbeck T, Friebel T, Friedman E, Hamann U, Huo D, Kwong A
. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018; 39(5):593-620.
PMC: 5903938.
DOI: 10.1002/humu.23406.
View
9.
Ruiz-Flores P, Sinilnikova O, Badzioch M, Calderon-Garciduenas A, Chopin S, Fabrice O
. BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat. 2002; 20(6):474-5.
DOI: 10.1002/humu.9084.
View
10.
Ruiz de Garibay G, Fernandez-Garcia I, Mazoyer S, Leme de Calais F, Ameri P, Vijayakumar S
. Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. Hum Mutat. 2021; 42(11):1488-1502.
DOI: 10.1002/humu.24276.
View
11.
Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S
. BRCA genes: BRCA 1 and BRCA 2. J BUON. 2018; 23(4):862-866.
View
12.
Luo C, Li N, Lu B, Cai J, Lu M, Zhang Y
. Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019. Chin Med J (Engl). 2021; 135(1):42-51.
PMC: 8850868.
DOI: 10.1097/CM9.0000000000001814.
View
13.
Herzog J, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S
. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. NPJ Breast Cancer. 2021; 7(1):107.
PMC: 8377150.
DOI: 10.1038/s41523-021-00317-6.
View
14.
Villarreal-Garza C, Weitzel J, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos M, Gallardo L
. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat. 2015; 150(2):389-94.
PMC: 4532439.
DOI: 10.1007/s10549-015-3312-8.
View
15.
Blazer K, Chavarri-Guerra Y, Garza C, Nehoray B, Mohar A, Daneri-Navarro A
. Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico. JCO Glob Oncol. 2021; 7:992-1002.
PMC: 8457783.
DOI: 10.1200/GO.20.00587.
View
16.
Maxwell K, Wubbenhorst B, Wenz B, De Sloover D, Pluta J, Emery L
. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017; 8(1):319.
PMC: 5567274.
DOI: 10.1038/s41467-017-00388-9.
View
17.
Lv L, Zhao B, Kang J, Li S, Wu H
. Trend of disease burden and risk factors of breast cancer in developing countries and territories, from 1990 to 2019: Results from the Global Burden of Disease Study 2019. Front Public Health. 2023; 10:1078191.
PMC: 9884979.
DOI: 10.3389/fpubh.2022.1078191.
View
18.
Mekonnen N, Yang H, Shin Y
. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Front Oncol. 2022; 12:880643.
PMC: 9247200.
DOI: 10.3389/fonc.2022.880643.
View
19.
Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A
. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; .
DOI: 10.1002/ijc.33588.
View
20.
Weitzel J, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C
. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol. 2012; 31(2):210-6.
PMC: 3532393.
DOI: 10.1200/JCO.2011.41.0027.
View